NCT06782555 - A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

January 31, 2028

Conditions

Metastatic Prostate CancerMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Pancreatic Cancer

Interventions

DRUG

Evofosfamide

Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.

DRUG

Zalifrelimab

Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.

DRUG

Balstilimab

Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston